MedPath

A prospective study evaluating efficacy of ALA HCl for diagnosis of upper urinary tract urothelial carcinoma

Not Applicable
Conditions
pper urinary tract urothelial carcinoma
Registration Number
JPRN-UMIN000031205
Lead Sponsor
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Brief Summary

Based on the results for these 18 patients, the sensitivity and specificity of ALA-PDD were calculated to be 80.0% and 33.3%, respectively, whereas for white light observation the respective values were 86.7% and 66.7% (Table 2). The PPV and NPV of ALA-PDD were 59.5% and 70.0%, respectively. The combined observation had the highest sensitivity at 72.5%, but the lowest specificity at 51.9%.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with allergy to ALA HCl or porphyrin, light hypersensitivity Patients with administration of the drugs which are contraindicated contraindication with ALA HCl Pregnant or lactating woman Patients with severe underlying diseases such as cardiovascular event, liver disfunction, diabetes mellitus, and so on. Patients who have been enrolled into another study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath